

Thyroid Hormone Analogues: An Update

Riccardo Zucchi

The development of thyroid hormone (TH) analogues was prompted by the attempt to exploit the effects of TH on lipid metabolism, avoiding cardiac thyrotoxicosis. Analysis of the relative distribution of the α and β subtypes of nuclear TH receptors (TR α and TR β) showed that TR α and TR β are responsible for cardiac and metabolic responses, respectively. Therefore, analogues with TR β selectivity were developed, and four different compounds have been used in clinical trials: GC-1 (sobetirome), KB-2115 (eprotirome), MB07344/VK2809, and MGL-3196 (resmetirom). Each of these compounds was able to reduce low-density lipoprotein cholesterol, but a phase 3 trial with eprotirome was interrupted because of a significant increase in liver enzymes and the contemporary report of cartilage side effects in animals. As a consequence, the other projects were terminated as well. However, in recent years, TR β agonists have raised new interest for the treatment of nonalcoholic fatty liver disease (NAFLD). After obtaining excellent results in experimental models, clinical trials have been started with MGL-3196 and VK2809, and the initial reports are encouraging. Sobetirome turned out to be effective also in experimental models of demyelinating disease. Aside TR β agonists, TH analogues include some TH metabolites that are biologically active on their own, and their synthetic analogues. 3,5,3'-triiodothyroacetic acid has already found clinical use in the treatment of some cases of TH resistance due to TR β mutations, and interesting results have recently been reported in patients with the Allan–Herndon–Dudley syndrome, a rare disease caused by mutations in the TH transporter MCT8. 3,5-diiodothyronine (T2) has been used with success in rat models of dyslipidemia and NAFLD, but the outcome of a clinical trial with a synthetic T2 analogue was disappointing. 3-iodothyronamine (TIAM) is the last entry in the group of active TH metabolites. Promising results have been obtained in animal models of neurological injury induced by β -amyloid or by convulsive agents, but no clinical data are available so far.

Keywords: TH analogues, sobetirome, eprotirome, resmetirom, triac, 3,5-diiodothyronine, 3-iodothyronamine

Introduction

THE TERM THYROID HORMONE (TH) analogue is used with regard to compounds that have a similar molecular structure as TH and can therefore interact with at least some of its molecular targets.

It should be kept in mind that TH signaling is particularly complex. Canonical TH signaling is based on the interaction with nuclear TH receptors (TRs), leading to either activation or repression of the transcription of a large number of genes. Two gene subtypes exist, TR α and TR β , and different isoforms, which are designated by numerical subscripts, can be produced by alternative splicing (1). TR α 1 is the major TR isoform in the heart, and it is also expressed in other tissues, including skeletal

muscle, brain, and bone. TR α 2 lacks part of the TH binding domain, so it is unable to bind TH and is thought to mediate constitutive repression of transcription. TR β 1 is widely expressed in most tissues, while TR β 2 expression is more circumscribed and it is particularly relevant in the brain, pituitary, retina, and inner ear. TR β 3 has been identified in rat adipose tissue, but it does not appear to be present in humans.

With regard to the topic of this review, the main functional consequence of TR subtype distribution is that the metabolic effects of TH are largely mediated by TR β 1, while cardiac TH actions depend on TR α 1.

In addition to canonical signaling, TH may activate a number of noncanonical signaling pathways (2). The latter involves TRs that do not bind DNA directly, extranuclear

Department of Pathology, University of Pisa, Pisa, Italy.

© Riccardo Zucchi 2020; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are cited.

TRs that activate the phosphatidylinositol 3-kinase pathway, and membrane receptors belonging to the integrin family (3).

In addition, some TH metabolites have been suggested to be potentially active, although their physiological role is still unclear. By definition, these compounds should be regarded as TH analogues, although they are endogenous molecules. They have also been used as templates to develop novel classes of synthetic analogues. Active TH metabolites include 3,5-diiodothyronine (T2), 3-iodothyronamine (T1AM), and several thyroacetic acids (3,5,3',5'-tetraiodothyroacetic acid or Tetrac; 3,5,3'-triiodothyroacetic acid or Triac; 3-iodothyroacetic acid or TA1). They have been the object of several recent reviews (4–8), and their properties are briefly recalled in the subsequent paragraphs only in as much as this is relevant to the object of the present succinct review.

TH analogues have been developed for clinical and therapeutic purposes, namely, to exploit some aspects of TH signaling to produce beneficial effects in the disease. Therefore, in the following paragraphs, these analogues are discussed with the perspective of their potential therapeutic use. Special emphasis is placed on clinical investigations, although some results obtained in experimental models of disease are mentioned when appropriate.

TH Analogues with Selective TR β Activity in Dyslipidemia

The development of selective TR β agonists was prompted by the aim of treating dyslipidemia, particularly hypercholesterolemia, avoiding cardiac thyrotoxicosis. The ligand binding pocket is more flexible in TR β than in TR α and one of the amino acids involved in triiodothyronine (T3) binding is different, since TR α serine 277 is replaced by asparagine 311 in TR β . These differences have been exploited to synthesize selective TR β agonists (9,10).

The analogues that have reached the clinical field are shown in Figure 1. In GC-1, now called sobetirome, the iodine atoms and the oxygen linking the two aromatic rings are

replaced by alkyl groups, and the amino acid side chain is replaced by an oxoacetic chain. The ratio of TR β to TR α affinity is 10-fold higher for GC-1 than for T3, and an additional useful property is represented by selective liver uptake.

In KB-2115, now referred to as eprotirome, iodine is replaced by bromine (in the tyrosyl ring) or isopropyl (in the phenolic ring) and an amido-acetic side chain is present, yielding nearly 20-fold TR β selectivity.

A different strategy was followed by researchers at Metabasis. Their compound, known as MB07811 and now renamed VK2809, is a prodrug, selectively taken up by the liver, where it is converted into the active principle (MB07344), which differs from GC-1 only for the presence of a phosphoryl group in the side chain.

Another compound that has been used in human is MGL-3196, also called resmetirom, whose more complex chemical structure (a substituted pyridazinone ring replaces the phenolic ring and a heterocyclic cyanoazauracil group is included in the side chain) allows nearly 30-fold TR β selectivity.

All these compounds have been used in animal models of hypercholesterolemia, where they reduced total and low-density lipoprotein (LDL) cholesterol without significant changes in heart rate (11). Based on these preclinical findings, clinical trials were started. In 2008, both sobetirome (12) and eprotirome (13) were reported to produce a significant reduction in total and LDL cholesterol after 2–3 weeks of treatment in small groups of patients affected by hypercholesterolemia. Similar results were obtained with MGL-3196, which reduced serum triglycerides and LDL cholesterol after 2 weeks of treatment in 48 hypercholesterolemic patients (14). In patients treated with statins, the addition of eprotirome caused further reduction in serum LDL cholesterol and triglycerides (15).

No significant side effects were reported in any of these investigations, and therefore, a phase 3 trial was undertaken to compare eprotirome (at the daily doses of 50 and 100 μ g) versus placebo in 236 patients with familial hypercholesterolemia. After 6 weeks, total cholesterol, LDL cholesterol,




FIG. 1. Chemical structure of the synthetic TR β analogues that have been used in clinical trials. In the left lower panel, please note that MB07811, now known as VK2809, is a prodrug; in the liver, it is converted into the active principle, formerly known as MB07344, by the hydroxylase CYP3A in a reaction requiring glutathione (GSH). See text for further details.

and triglycerides were significantly reduced in both treatment groups, without any change in HDL cholesterol (16). However, the trial was interrupted (it was originally planned to last 52–76 weeks) because parallel experimental investigations found that eprotirome caused cartilage damage in dogs. Notably, during the study period, a significant increase in liver enzymes was detected, which determined treatment interruption in four patients.

Resulting in a partial domino effect, termination of the eprotirome project caused parallel projects to be terminated as well. In particular, the sobetirome project was interrupted and Metabasis announced that a phase 1 investigation with MB07344 was aborted after observing increased liver enzymes in some patients. Additional reasons probably contributed to these decisions. While selective TR β agonists were devised and tested, excellent clinical results were obtained with statins in the primary and secondary preventions of major cardiac events. At the same time, investigations performed with other experimental drugs showed that LDL cholesterol reduction *per se* was not necessarily associated with reduced cardiovascular risk. In aggregate, selective TR β stimulation was no longer regarded as a promising strategy to treat hypercholesterolemia.

TH Analogues with Selective TR β Activity in Liver Disease

Despite the disappointing results obtained with TR β agonists in hypercholesterolemia, in recent years new potential uses have been proposed for these agents. The most attractive field is probably represented by nonalcoholic fatty liver disease (NAFLD).

This is a highly prevalent condition, since it is estimated to affect 17–46% of the adult population in the United States and Europe (17). Its clinical presentation is quite variable. Most NAFLD patients show a simple increase in liver enzymes with a histological pattern of increased hepatocyte triglyceride (steatosis). Symptoms may be minimal or absent and the clinical picture may be stable over time. However, a significant fraction of NAFLD patients (up to 40% in some series) develop histological evidence of lobular inflammation and hepatocyte ballooning, defining a variant of the disease known as nonalcoholic steatohepatitis (NASH). NASH is a serious condition, since it is associated with a high risk (about 10–20%) of evolution into cirrhosis, that is, derangement in liver architecture leading to hepatic insufficiency. Patients with NASH and/or cirrhosis are also prone to develop hepatocellular carcinoma (HCC).

NAFLD is frequently associated with insulin resistance, hypercholesterolemia, or other components of the so-called metabolic syndrome (17) and patients are usually treated for these underlying conditions, but no specific treatment to prevent liver damage has been approved so far. In principle, TH should be beneficial in NAFLD, due to reduced fatty acid synthesis, increased triglyceride and fatty acid breakdown, and enhanced hepatocyte regeneration (18,19). The liver effects of TH are mediated by TR β , so selective TR β agonists have been tested in experimental models, and several compounds (including sobetirome, eprotirome, and MB07811) were able to reduce liver steatosis (18–20). Sobetirome was also reported to prevent the development of HCC induced by activation of the catenin pathway (21).

The study of TR β agonists in NAFLD has just entered the clinical field, and the results of two clinical trials have recently been reported. In 116 patients with biopsy-confirmed NASH treated with MGL-3196 (resmetirom) (80 mg daily) for 12 weeks, liver fat, as assessed by magnetic resonance imaging, was significantly reduced: –7.0% versus –2.7% with placebo, if expressed as percentage of absolute liver mass; –32.9% versus –10.4% if expressed as percentage of baseline liver fat (22). The effect was retained after 36 weeks, and in a subgroup of patients, biopsy revealed a reduction of histological markers of inflammation.

Similar results were reported with VK2809 (alias MB07811) in 45 patients with NAFLD treated for 12 weeks at the dosages of 10 mg every other day or 10 mg daily (23). In this trial, liver fat content, assessed by magnetic resonance imaging, decreased by 8.9–10.6% versus 0.9% with placebo (–56.5–59.7% vs. –8.9% if expressed as percentage of baseline liver fat). While these results have raised a great interest, and discussions have already started about the comparison of these two drugs, it should be stressed that the final results of the latter trial have not been published yet.

TH Analogues with Selective TR β Activity in Central Nervous System Disease

In recent years, theoretical arguments have been developed, suggesting the potential usefulness of TH analogues in demyelinating disease, since TH favors both oligodendrocyte differentiation and myelin sheet synthesis (24). Although TR α 1 is widely expressed in the central nervous system, efforts have been focused on TR β agonists because of the necessity to avoid cardiac side effects. To increase bioavailability, an ethanolamine ester of sobetirome has been synthesized, which acts as a prodrug, since it crosses the blood/brain barrier and is converted into sobetirome within the central nervous system (25). This compound has been recently tested in different experimental models of demyelination, with good results: biochemical evidence of remyelination was confirmed by morphological findings obtained by nuclear magnetic imaging, and it was associated with improved functional recovery (26).

Clinical tests may be imminent for a specific disease known as X-linked adrenoleukodystrophy (ALD). This is a rare congenital disease due to mutations in the ALD protein, a transporter for very-long-chain fatty acids (i.e., with ≥ 22 carbon atoms), physiologically located in the peroxisomal membrane and encoded by the *ABCD1* gene. The consequence is the accumulation of very-long-chain fatty acids and their derivatives, which are eventually incorporated in cellular membranes, whose structure and function are deranged. Affected males develop adrenal insufficiency in childhood and progressive myelopathy occurs in adulthood. Demyelinating lesions in cerebral white matter also appear, since the age of 3 years (27).

ALD patients may benefit from hematopoietic stem cell transplantation, but this treatment is effective only if performed in the early stages of the disease, and it carries a significant risk of mortality (5–10%). No specific pharmacological therapy is available for ALD. Notably, TH induces the expression of *ABCD2*, coding for an additional peroxisomal transporter, and in a transgenic mouse model of ALD, sobetirome administration reduced the brain and adrenal

content of very-long-chain fatty acids (28). Based on these observations, a clinical trial with sobetirome in X-linked ALD has been posted in the NIH database (NCT01787578). The trial is presently labeled as withdrawn, and the alleged reason is the need for revisions to the original protocol.

Triac in Syndromes of Reduced Sensitivity to TH

Reduced sensitivity to TH is diagnosed when symptoms of hypothyroidism occur despite normal or increased serum TH. This finding may be the consequence of mutations in TRs, transporters, or metabolizing enzymes (29). The expression “resistance to TH” is usually reserved for syndromes caused by TR mutations. Most cases are associated with TR β mutations. Since TR β is involved in the inhibition of thyrotropin (TSH) secretion by T3 and thyroxine (T4), circulating levels of T4 and T3 are usually high, TSH is normal or high, and goiter may be present. The clinical picture is quite variable, and includes signs and symptoms of both hypothyroidism, in TR β -dependent organs, and thyrotoxicosis, in TR β -dependent organs. The most common findings are delayed growth, delayed bone maturation, cognitive impairment, and tachycardia (1,29).

Treating TH resistance is not easy. Exogenous T4 or T3 administration may improve some symptoms, but it may worsen others, and symptomatic therapy is often prescribed, for example, beta-blockers to reduce heart rate. The ideal treatment would be represented by a T3 analogue able to activate the mutated receptor.

In some patients, this can occur with Triac (Fig. 2). The lack of the amine group does not prevent Triac from activating TRs, and it has similar affinity as T3 for the wild-type receptor. Apparently, the different shape and charge of the Triac molecule allow several classes of mutated TR β to be activated as well. In these patients, chronic Triac administration at dosages on the order of 25–35 μg per kg of body weight daily represents the best therapeutic regimen (30). In general, Triac-sensitive cases of TH resistance are caused by mutations in the carboxy-terminal region of the T3 binding

domain, while mutations located close to the hinge region do not respond to Triac. No positive response to Triac has been reported in TR α mutations, so far.

A different cause of reduced sensitivity to TH is represented by mutations in MCT8, a T3/T4 transporter that is the major pathway mediating T4 and T3 uptake in the central nervous system (31). The clinical syndrome associated with MCT8 mutations is known as the Allan–Herndon–Dudley syndrome. The *MCT8* gene is located on the X chromosome, and therefore, virtually all patients are male. Diagnosis is suspected in the presence of high T3 with low to normal T4 and low to normal TSH, associated with congenital brain hypothyroidism. The phenotype is variable, depending on the location and type of the mutation. Symptoms usually include cognitive impairment associated with congenital hypotonia and weakness, which may progress to spasticity. Paroxysmal dyskinesias and seizures may also occur. Peripheral hyperthyroidism often causes tachycardia, muscle wasting, and progressive body weight reduction (31–33).

Since it has been observed that cellular Triac uptake does not depend on MCT8, a clinical trial has been undertaken with this endogenous TH analogue in 50 patients, with a median age of 7 years. The results obtained after 12 months of treatment at the dosage of 350–4200 μg daily have recently been published (33). The treatment was highly effective in reducing serum T3, and Triac dosage was actually titrated on T3 reduction. Signs of peripheral hypothyroidism, notably tachycardia and body weight reduction, were significantly attenuated. On the contrary, the effects on the neurological symptoms were limited, and improvement in the indices of motor function was limited to patients younger than 5 years. It seems therefore that once the neurological phenotype is fully developed, it is hardly reversible.

On this basis, another phase 2 trial is underway (NCT02396459), in which Triac treatment will be started as early as possible in postnatal life.

Synthetic TH analogues might also be useful. Notably, in a small clinical study diiodothyropropionic acid (DITPA) administration (2.1–2.4 mg/kg per day) was able to normalize T3 in four children affected by MCT8 deficiency, aged 8–25 months (34). Heart rate decreased in three patients and weight gain occurred in two. Although DITPA was introduced over 25 years ago as a relatively weak and poorly selective TR agonist, its mode of interaction with TRs has not been specifically investigated so far.

Potential Uses of T2 and T1AM

While Triac is basically a thyromimetic, other active TH metabolites (Fig. 2) can interact with different molecular targets. T2 has direct mitochondrial actions, allegedly on respiratory chain complex IV (subunit Va), and it stimulates mitochondrial respiration and fatty acid oxidation (3,4,8). These metabolic responses are further supported by genomic effects, whose molecular basis is unclear, since they appear to be different from those elicited by T3. In any case, in rats treated with high-fat diet, exogenous T2 decreased serum triglycerides and LDL cholesterol, as well as liver fat and biochemical indices of liver injury, suggesting potential therapeutic value for either dyslipidemia or NAFLD (4,35). However, it is still controversial whether these positive




FIG. 2. Chemical structure of some active thyroid hormone metabolites that have been used in patients or in animal models of human disease. See text for further details.

effects may be achieved without inducing tachycardia or cardiac hypertrophy, since cardiac thyrotoxicosis has been reported in mice (36).

A single pilot investigation was performed in two human volunteers taking T₂ (300 µg/kg) for 3 weeks (37). A slight but significant decrease in body weight was reported (−4%), without any change in serum T₃, T₄, TSH, and cardiac function. More recently, a synthetic T₂ analogue (TRC150094) was used in 40 patients with metabolic syndrome, but the results were rather disappointing, since no significant effect on insulin sensitivity and plasma lipid profile was observed (38).

The last entry into the group of active TH metabolites is represented by T1AM. It does not interact with canonical or noncanonical TH targets, and it was discovered as a high affinity agonist of TAAR1, a membrane G protein-coupled receptor (GPCR) that is expressed in the brain and many other tissues (39,40). T1AM is a biogenic amine and shares several properties of this class of compounds, including the ability to interact with multiple targets, namely, other GPCRs (e.g., α_{2A} adrenergic receptor), membrane ionic channels (e.g., TRPM8), and monoamine transporters (6,7).

In experimental animals, the administration of exogenous T1AM induced many different functional effects. Neurological and metabolic effects are particularly interesting, since they appear to be elicited at relative low doses, and might have physiological relevance (40,41). The former includes modulation of feeding behavior and sleep/wake cycle, reduction of pain threshold, prolearning, and anti-amnesic responses. The major metabolic effects consist in the stimulation of triglyceride and fatty acid catabolism, but anti-insulin effects on glucose metabolism are also elicited at slightly higher doses.

Although the administration of exogenous T1AM has not been tested in humans, some experimental results obtained in murine models of disease have raised interest about potential therapeutic applications. T1AM reduced serum cholesterol in spontaneously obese mice (42), as well as liver triglycerides in a mouse model of polycystic ovary syndrome (43).

Neuroprotective effects appear even more promising. Intracerebral T1AM rescued long-term potentiation and behavioral evidence of cognitive dysfunction in an *in vivo* model of β -amyloid toxicity, namely, transgenic mice overexpressing human-mutated amyloid precursor protein (44). In addition, the intracerebral injection of T1AM metabolite 3-iodothyroacetic acid protected from the convulsive effect of pentylene-tetrazole and from kainate toxicity (45), while exogenous T1AM reduced apoptosis and functional injury in a mouse model of spinal cord clamp (46).

Because of the multitude of T1AM effects, an active research line is focused on the development of synthetic derivatives with more favorable biodistribution and/or receptor selectivity (47).

In conclusion, the development TH analogues was initially prompted by the attempt to exploit the effects of TH on lipid metabolism, while avoiding unwanted cardiac effects. TR β agonists have provided good results in a few small clinical trials performed in hypercholesterolemic patients, but these projects have been terminated after the report of potential side effects. In recent years, TR β agonists have raised new interest for the treatment of NAFLD, and a

couple of clinical trials have provided encouraging initial results. Triac has already found clinical use in the treatment of selected cases of TH resistance due to TR β mutations, and interesting results have recently been reported in the Allan–Herndon–Dudley syndrome.

Other TH analogues are under consideration for neurological diseases, although human results are not yet available. In particular, sobetirome derivatives have been successful in animal models of multiple sclerosis, and T1AM has been beneficial in an animal model of β -amyloid toxicity.

Overall, research on TH analogues is experiencing a shift in its focus, but it still appears to be an active and promising field.

Author Disclosure Statement

No competing financial interests exist.

Funding Information

This work was supported by a grant from Pisa University (PRA 2018 to R.Z.).

References

1. Ortiga-Carvalho TM, Sidhaye AR, Wondisford FE 2014 Thyroid hormone receptors and resistance to thyroid hormone disorders. *Nat Rev Endocrinol* **10**:582–591.
2. Flamant F, Cheng SY, Hollenberg AN, Moeller LC, Samarut J, Wondisford FE, Yen PM, Refetoff S 2017 Thyroid hormone signaling pathways: time for a more precise nomenclature. *Endocrinology* **158**:2052–2057.
3. Davis PJ, Goglia F, Leonard JL 2016 Nongenomic actions of thyroid hormone. *Nat Rev Endocrinol* **17**:111–121.
4. Senese R, de Lange P, Petit G, Moreno M, Goglia F, Lanni A 2018 3,5-diiodothyronine: a novel thyroid hormone metabolite and a potent modulator of energy metabolism. *Front Endocrinol (Lausanne)* **9**:427.
5. Groeneweg S, Peeters RP, Visser TJ, Visser WE 2017 Triiodothyroacetic acid in health and disease. *J Endocrinol* **234**:R99–R121.
6. Hoefig CS, Zucchi R, Köhrle J 2016 Thyronamines and derivatives: physiological relevance, pharmacological actions, and future research directions. *Thyroid* **26**:1656–1673.
7. Köhrle J, Biebermann H 2019 3-iodothyronamine—a thyroid hormone metabolite with distinct target profiles and modes of action. *Endocrine Rev* **40**:602–630.
8. Zucchi R, Rutigliano G, Saponaro F 2019 Novel thyroid hormones. *Endocrine* **66**:95–104.
9. Joharapurak AA, Dhote VV, Jain MR 2012 Selective thyromimetics using receptor and tissue selectivity approaches: prospects for dyslipidemia. *J Med Chem* **55**:5649–5675.
10. Mondal S, Muges G 2017 Novel thyroid hormone analogues, enzyme inhibitors and mimetics, and their action. *Mol Cell Endocrinol* **458**:91–104.
11. Tancevski I, Rudling M, Eller P 2011 Thyromimetics: a journey from bench to bed-side. *Pharmacol Ther* **131**:33–39.
12. Lin VW, Klepp HM, Hanley RM 2008 Sobetirome is a TR β - and liver-selective thyromimetic that can affect substantial LDL-C lowering without significant changes in heart rate or the thyroid axis in euthyroid men [abstract].

- San Francisco: the Endocrine Society Annual Meeting ENDO 08, OR36-33.
13. Berkenstam A, Kristensen J, Mellström K, Carlsson B, Malm J, Rehnmark S, Garg N, Andersson CM, Rudling M, Sjöberg F, Angelin B, Baxter JD 2008 The thyroid mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. *Proc Natl Acad Sci U S A* **105**:663–667.
 14. Taub R, Chiang E, Chabot-Blanchet M, Kelly MJ, Reeves RA, Guertin MC, Tardif JC 2013 Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor- β agonist. *Atherosclerosis* **230**:373–380.
 15. Ladenson PW, Kristensen JD, Ridgway EC, Olsson AG, Carlsson B, Klein I, Baxter JD, Angelin B 2010 Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. *N Engl J Med* **362**:906–916.
 16. Sjouke B, Langslet G, Ceska R, Nicholls SJ, Nissen SE, Ohlander M, Ladenson PW, Olsson AG, Hovingh GK, Kastelein JJ 2014 Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomized, double-blind, placebo-controlled phase 3 study. *Lancet Diabetes Endocrinol* **2**:355–463.
 17. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) 2016 EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol* **64**:1388–1402.
 18. Coppola M, Glinni D, Moreno M, Cioffi F, Silvestri E, Goglia F 2014 Thyroid hormone analogues and derivatives: actions in fatty liver. *World J Hepatol* **6**:114–129.
 19. Sinha RA, Singh BK, Yen PM 2018 Direct effects of thyroid hormones on hepatic lipid metabolism. *Nat Rev Endocrinol* **14**:259–269.
 20. Martagon AJ, Lin JZ, Cimini SL, Webb P, Phillips KJ 2015 The amelioration of hepatic steatosis by thyroid hormone receptor agonists is insufficient to restore insulin sensitivity in ob/ob mice. *PLoS One* **10**:e0122987.
 21. Puliga E, Min Q, Tao J, Zhang R, Pradhan-Sundt T, Poddar M, Singh S, Columbano A, Yu J, Momga SP 2017 Thyroid hormone receptor- β agonist GC-1 inhibits met- β -catenin-driven hepatocellular cancer. *Am J Pathol* **187**:2473–2485.
 22. Harrison SA, Bashir MR, Guy CD, Zhou L, Moylan CA, Frias JP, Alkhoury N, Bansal MB, Baum S, Neuschwander-Tetri BA, Taub R, Moussa SE 2019. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicenter, randomized, double-blind, placebo-controlled phase 2 trial. *Lancet* **394**:2012–2024.
 23. Looma R, Neutel J, Bernard D, Severance R, Mohseni R, Dao M, Saini S, Margaritescu C, Homer K, Tran B, Mancini M, Masamune H, Lian B 2018 VK2809, a novel liver-directed thyroid receptor beta agonist, significantly reduces liver fat in patients with nonalcoholic fatty liver disease: a phase 2 randomized placebo-controlled trial [abstract]. *Hepatology* **68**:1447A.
 24. Zhang M, Ma Z, Qin H, Yao Z 2016 Thyroid hormone potentially benefits multiple sclerosis via facilitating remyelination. *Mol Neurobiol* **53**:4406–4416.
 25. Placzek AT, Ferrara SJ, Hartley MD, Sanford-Crane HS, Meining M, Scanlan TS 2016 Sobetirome prodrug esters with enhanced blood-brain barrier permeability *Bioorg Med Chem* **24**:5842–5854.
 26. Hartley MD, Banerji T, Tagge IJ, Kirkemo LL, Chaudhary P, Calkins E, Galipeau D, Shokat MD, DeBell MJ, Van Leuven S, Miller H 2019 Myelin repair stimulated by CNS-selective thyroid hormone action. *JCI Insights* **4**:e126329.
 27. Kemp S, Huffnagel IC, Linthorst GE, Wanders RJ, Engels M 2016 Adrenoleukodystrophy—neuroendocrine pathogenesis and redefinition of natural history. *Nat Rev Endocrinol* **12**:606–615.
 28. Hartley MD, Kirkemo LL, Banerji T, Scanlan TS 2017 A thyroid hormone-based strategy for correcting the biochemical abnormality in X-linked adrenoleukodystrophy. *Endocrinology* **158**:1328–1338.
 29. Refetoff S, Dumitrescu AM 2007 Syndromes of reduced sensitivity to thyroid hormone: genetic defects in hormone receptors, cell transporters and deiodination. *Best Pract Clin Endocrinol Metabolism* **21**:277–305.
 30. Groeneweg S, Peeters RP, Visser TJ, Visser WE 2017 Therapeutic applications of thyroid hormone analogues in resistance to thyroid hormone (RTH) syndromes. *Mol Cell Endocrinol* **458**:82–90.
 31. Friesema ECH, Visser WE, Visser TJ 2010 Genetics and phenomics of thyroid hormone transport by MCT8. *Mol Cell Endocrinol* **322**:107–113.
 32. Schwartz CE, Stevenson RE 2007 The MCT8 thyroid hormone transporter and Allan-Herndon-Dudley Syndrome. *Best Pract Clin Endocrinol Metab* **21**:307–321.
 33. Groeneweg S, Peeters RP, Moran C, Stoupa A, Auriel F, Tonduti D, Dica A, Paone L, Rozenkova K, Malikova J, van der Walt A, de Coo IFM, McGowan A, Lyons G, Aarsen FK, Barca D, van Beynum IM, van der Knoop MM, Jansen J, Manshande M, Lunsing RJ, Nowak S, den Uil CA, Zillikens MC, Visser FE, Vrijmoeth P, de Wit MCY, Wolf NI, Zandstra A, Ambegaonkar G, Singh Y, de Rijke YB, Medici M, Bertini ES, Depoorter S, Lebl J, Cappa M, De Meirleir L, Krude H, Craiu D, Zibordi F, Oliver Petit I, Polak M, Chatterjee K, Visser TJ, Visser WE 2019 Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single arm, open-label, phase 2 trial. *Lancet Diabetes Endocrinol* **7**:695–706.
 34. Verge CF, Konrad D, Cohen M, Di Cosmo C, Dumitrescu AM, Marcinkowski T, Hameed S, Hamilton J, Weiss RE, Refetoff S 2012 Diiodothyronine acid (DITPA) in the treatment of MCT8 deficiency. *J Clin Endocrinol Metab* **97**:4515–4523.
 35. Goglia F 2015 The effects of 3,5-diiodothyronine on energy balance. *Front Physiol* **5**:528.
 36. Jonas W, Lietzow J, Wohlgemuth F, Hoefig CS, Wiedmer P, Schweizer U, Köhrl J, Schurmann A 2015 3,5-Diiodo-L-thyronine (3,5-T₂) exerts thyromimetic effects on hypothalamus-pituitary-thyroid axis, body composition, and energy metabolism in male diet-induced obese mice. *Endocrinology* **156**:389–399.
 37. Antonelli A, Fallahi P, Ferrari SM, Di Domenicantonio A, Moreno M, Lanni A, Goglia F 2011 3,5-diiodo-L-thyronine increases resting metabolic rate and reduces body weight without undesirable side effects. *J Biol Regul Homeost Agents* **25**:655–660.
 38. Van der Val F, Hassing C, Visser M, Thakkar P, Mohanan A, Pathak K, Dutt C, Chauthaiwale V, Ackermans M, Nederveen A, Serlie M, Nieuwdorp M, Stoes E 2014 The effect of a diiodothyronine mimetic on insulin sensitivity in male cardiometabolic patients: a double-blind randomized controlled trial. *PLoS One* **9**:e86890.

39. Zucchi R, Chiellini S, Scanlan TS, Grandy DK 2006 Trace amine-associated receptors and their ligands. *Br J Pharmacol* **149**:967–978.
40. Rutigliano G, Accorroni A, Zucchi R 2018 The case for TAAR1 as a modulator of central nervous system function. *Front Pharmacol* **8**:987.
41. Zucchi R, Accorroni A, Chiellini G 2014 Update on 3-iodothyronamine and its neurological and metabolic actions. *Front Physiol* **5**:402.
42. Assadi-Porter FM, Reiland H, Sabatini M, Lorenzini L, Carnicelli V, Rogowski M, Selen Alpergin ES, Tonelli M, Ghelardoni S, Saba A, Zucchi R, Chiellini G 2018 Metabolic reprogramming by 3-iodothyronamine (TIAM): a new perspective to reverse obesity through regulation of sirtuin 4 and 6 expression. *Int J Mol Sci* **19**:e1535.
43. Selen Alpergin ES, Bolandnazar Z, Sabatini M, Rogowski M, Chiellini G, Zucchi R, Assadi-Porter FM 2017 Metabolic profiling reveals reprogramming of lipid metabolic pathways in treatment of polycystic ovary syndrome with 3-iodothyronamine. *Physiol Rep* **5**:e13097.
44. Accorroni A, Rutigliano G, Sabatini M, Frascarelli S, Borsò M, Novelli E, Bandini L, Ghelardoni L, Saba A, Zucchi R, Origlia N 2020 Exogenous 3-iodothyronamine rescues the entorhinal cortex from β -amyloid toxicity. *Thyroid* **30**:147–160.
45. Laurino A, Landucci E, Resta F, De Siena F, Pellegrini-Giampietro DE, Masi A, Mannaioni G, Raimondi L 2018 Anticonvulsant and neuroprotective effects of the thyroid hormone metabolite 3-Iodothyroacetic Acid. *Thyroid* **28**:1387–1397.
46. Lv J, Liao J, Tan W, Yang L, Shi X, Zhang H, Chen L, Wang S, Li Q 2018 3-Iodothyronamine acting through an anti-apoptotic mechanism is neuroprotective against spinal cord injury in rats. *Ann Clin Lab Sci* **48**:736–742.
47. Chiellini G, Bellusci L, Sabatini M, Zucchi R 2017 Thyronamines and analogues—the route from rediscovery to translational research on thyronergic amines. *Mol Cell Endocrinol* **458**:149–155.

Address correspondence to:
Riccardo Zucchi, MD, PhD
Department of Pathology
University of Pisa
Via Roma 55
Pisa 56126
Italy

E-mail: riccardo.zucchi@unipi.it